Short description
BBsafe allows the presence of genomic sequences from the foetus and present in maternal blood to be studied and thus the level of risk for the corresponding syndrome to be determined. BBsafe tests are carried out by the Analiza Group laboratory in Spain.
BBSAFE ADVANCE
Trisomy 21 (Down’s Syndrome) Trisomy 18 (Edwards’ Syndrome) Trisomy 13 (Patau’s Syndrome) Sex chromosome aneuploidies (Turner syndrome, Klinefelter syndrome, XYY syndrome ...). Foetal sexing (for patients who choose this); the 7 most common microdeletion Syndromes. In addition, all chromosomes are analysed, providing the most information possible to date from non-invasive prenatal tests.
NON-INVASIVE PRENATAL TEST BBSAFE • ADVANCE
Short description
BBsafe allows the presence of genomic sequences from the foetus and present in maternal blood to be studied and thus the level of risk for the corresponding syndrome to be determined. BBsafe tests are carried out by the Analiza Group laboratory in Spain.
BBSAFE ADVANCE
Trisomy 21 (Down’s Syndrome) Trisomy 18 (Edwards’ Syndrome) Trisomy 13 (Patau’s Syndrome) Sex chromosome aneuploidies (Turner syndrome, Klinefelter syndrome, XYY syndrome ...). Foetal sexing (for patients who choose this); the 7 most common microdeletion Syndromes. In addition, all chromosomes are analysed, providing the most information possible to date from non-invasive prenatal tests.
€695.00
Tax included
WHAT’S IT FOR?
The Non-invasive Prenatal Test is a screening test (not a definitive test) which allows chromosomal abnormalities in a foetus to be detected through a blood test on the mother.
WHAT DOES BBSAFE PLUS DETECT?
Trisomy 21 (Down’s Syndrome) Trisomy 18 (Edwards’ Syndrome) Trisomy 13 (Patau’s Syndrome) Sex chromosome aneuploidies (Turner syndrome, Klinefelter syndrome, XYY syndrome ...). Foetal sexing (for patients who choose this); the 7 most common microdeletion Syndromes. In addition, all chromosomes are analysed, providing the most information possible to date from non-invasive prenatal tests.
WHAT DOES IT CONSIST OF?
Blood analysis of the pregnant woman without any kind of risk to the foetus.
WHO’S IT FOR?
It can be done from 10 weeks’ pregnancy in single pregnancy and from 12 weeks in multiple pregnancies, although it is recommended to carry it out from 12 weeks in single pregnancies and 14 in multiple pregnancies.
TECHNICAL SPECIFICATIONS
Type of sample: 20 ml of peripheral blood collected in two Streck Cell-Free DNA BCT® tubes (provided by our laboratory), from week 10 in single pregnancy and week 12 in twin pregnancy.
Delivery of results: 9 working days
Requirements: Prescription from a medical specialist in Gynaecology and Obstetrics, who will advise the patient in cases of results of high risk and who should carry out patient follow-up. It is necessary to fill in the application form and the informed consent included in the collection kit supplied by the laboratory.
This test can only be carried out at the Centro Principe de Vergara 40, 28001 Madrid
13 other products in the same category:
